Francisco Trust Under Agreemen Sells 40,000 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 40,000 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $1.98, for a total transaction of $79,200.00. Following the transaction, the insider directly owned 3,410,664 shares in the company, valued at approximately $6,753,114.72. This represents a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Performance

Dyadic International stock opened at $1.06 on Wednesday. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The company has a market capitalization of $38.63 million, a PE ratio of -4.61 and a beta of 1.15. The firm has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.83. Dyadic International Inc. has a twelve month low of $0.65 and a twelve month high of $1.35.

Dyadic International (NASDAQ:DYAI) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Research analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Dyadic International News Summary

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Trading of Dyadic International

A number of institutional investors have recently modified their holdings of the company. Apis Capital Advisors LLC purchased a new position in Dyadic International during the 3rd quarter valued at about $1,817,000. Marathon Capital Management bought a new stake in shares of Dyadic International in the 3rd quarter worth approximately $41,000. Bank of America Corp DE grew its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International during the third quarter valued at approximately $190,000. Finally, Geode Capital Management LLC increased its stake in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.